Hucog HP (Highly Purified Human Chorionic Gonadotropin) represents a significant advancement in reproductive medicine formulations. This pharmaceutical-grade hormone is engineered to mimic the natural luteinizing hormone surge, triggering final follicular maturation and ovulation in controlled ovarian stimulation protocols. Manufactured under stringent quality controls, Hucog HP offers reliable biological activity with minimal impurities, making it an essential component in assisted reproductive technology cycles. Its high purification standard ensures consistent performance while reducing the risk of adverse reactions, providing fertility specialists with a predictable tool for optimizing treatment outcomes.

Features

• Contains highly purified human chorionic gonadotropin (hCG) derived from recombinant DNA technology
• Available in standardized doses: 1000 IU, 2000 IU, 5000 IU, and 10,000 IU vials
• Lyophilized powder formulation for enhanced stability and reconstitution accuracy
• Low protein content (≤0.5 mg per 1000 IU) reducing immunogenic potential
• Precisely calibrated biological activity (within ±10% of labeled potency)
• Manufactured in compliance with cGMP standards and EMA/FDA regulations
• Includes solvent (bacteriostatic water) for reconstitution in separate ampoule
• Rubber-stoppered vials maintain sterility and facilitate accurate withdrawal

Benefits

• Precise Ovulation Induction: Enables accurate timing of ovulation for optimal fertilization window in ART cycles
• Enhanced Follicular Maturation: Promotes final cytoplasmic and nuclear maturation of oocytes, improving egg quality
• Reliable Luteal Phase Support: Supports corpus luteum function and progesterone production post-ovulation
• Reduced Immunogenicity: High purification minimizes antibody formation with repeated use
• Consistent Biological Response: Standardized potency ensures predictable clinical outcomes across treatment cycles
• Flexible Dosing Options: Multiple strength availability allows for personalized treatment protocols

Common use

Hucog HP is primarily indicated for the final maturation of follicles in women undergoing controlled ovarian hyperstimulation as part of assisted reproductive technology (ART) procedures, including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). It is administered when monitoring indicates adequate follicular development, typically when leading follicles reach 17-20 mm diameter with appropriate estradiol levels. Additionally, it is used in ovulation induction protocols for anovulatory or oligo-ovulatory women when other methods have proven insufficient. In male patients, Hucog HP may be prescribed for hypogonadotropic hypogonadism to stimulate testosterone production and spermatogenesis.

Dosage and direction

For ovulation induction in women: 5,000–10,000 IU administered as a single intramuscular injection 24–48 hours after the last dose of gonadotropins. Exact timing should be based on follicular monitoring and endocrine parameters.

For controlled ovarian stimulation in ART: 250 mcg (approximately 6,500 IU) subcutaneously or intramuscularly when optimal follicular development is achieved. Some protocols may use 5,000–10,000 IU based on patient response.

For male hypogonadotropic hypogonadism: 1,000–4,000 IU administered intramuscularly 2–3 times weekly for several months. Dosage should be titrated based on testosterone response and spermatogenesis parameters.

Reconstitution: Add 1–2 mL of provided bacteriostatic water to the lyophilized powder. Gently swirl until completely dissolved—do not shake vigorously. Use immediately after reconstitution.

Precautions

• Strict adherence to aseptic technique during reconstitution and administration is mandatory to prevent microbial contamination
• Ovarian hyperstimulation syndrome (OHSS) risk assessment must be performed prior to administration
• Patients with polycystic ovary syndrome require careful monitoring due to increased OHSS susceptibility
• Multiple pregnancy risk should be discussed thoroughly with patients before treatment initiation
• Regular ultrasound monitoring and estradiol measurements are essential throughout treatment
• History of allergic reactions to hCG or other gonadotropins warrants careful consideration
• Patients with renal or hepatic impairment require dose adjustment and enhanced monitoring
• Cardiovascular status should be evaluated in patients with pre-existing cardiac conditions

Contraindications

• Primary ovarian failure (elevated FSH levels indicating non-responsive ovaries)
• Uncontrolled thyroid or adrenal dysfunction
• Organic intracranial lesions such as pituitary tumors
• Abnormal uterine bleeding of undetermined etiology
• Ovarian cysts or enlargement not related to polycystic ovary syndrome
• Hypersensitivity to hCG or any component of the formulation
• Pregnancy (except in specific protocols under specialist supervision)
• Active thromboembolic disorders
• Hormone-dependent malignancies of reproductive organs

Possible side effect

Common (≥1/100)

• Injection site reactions: pain, erythema, swelling, or bruising
• Mild ovarian enlargement with abdominal discomfort
• Headache and fatigue
• Mild fluid retention

Less common (≥1/1000)

• Ovarian hyperstimulation syndrome (OHSS) ranging from mild to severe
• Breast tenderness and enlargement
• Mood swings and irritability
• Nausea and gastrointestinal disturbances
• Allergic reactions including urticaria and rash

Rare (<1/1000)

• Arterial thromboembolism
• Ovarian torsion
• Ectopic pregnancy
• Anaphylactic reactions
• Precocious puberty in children

Drug interaction

• Concomitant use with other gonadotropins may potentiate ovarian response and increase OHSS risk
• Corticosteroids may alter metabolic clearance of hCG
• Dopamine agonists might reduce pituitary response to hCG
• Anticoagulants require careful monitoring due to potential increased thrombosis risk
• Hormonal contraceptives may interfere with treatment efficacy
• Medications affecting pituitary-gonadal axis function should be used with caution

Missed dose

In fertility treatment protocols, timing is critical. If a scheduled injection is missed, contact the treating physician immediately. Do not administer a double dose to make up for a missed injection. The treatment cycle may need to be reassessed based on the timing of the missed dose relative to follicular development. For male patients on long-term therapy, resume the regular dosing schedule as soon as possible.

Overdose

Excessive dosing may lead to severe ovarian hyperstimulation syndrome characterized by rapid ovarian enlargement, ascites, pleural effusion, and hemodynamic instability. In males, overdose may cause excessive androgen production leading to acne, fluid retention, and gynecomastia. Treatment is symptomatic and supportive, including hospitalization for severe OHSS with fluid management, thromboprophylaxis, and monitoring of vital signs and laboratory parameters. Dialysis is not effective for hCG removal due to its large molecular size.

Storage

Store unopened vials at 2–8°C (36–46°F) in the original packaging to protect from light. Do not freeze. After reconstitution, the solution should be used immediately. If necessary, reconstituted solution may be stored at 2–8°C for up to 24 hours. Discard any unused portion. Do not use if solution appears cloudy or contains particulate matter. Keep out of reach of children.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Treatment with Hucog HP should only be administered under the supervision of a qualified healthcare professional experienced in fertility treatments. Individual patient responses may vary, and treatment protocols should be tailored to specific medical circumstances. Always follow the prescribing information provided with the medication and consult with your healthcare provider regarding any questions or concerns about your treatment.

Reviews

“Hucog HP has become our standard hCG preparation for trigger shots in IVF cycles. The consistent potency and low immunogenicity profile make it reliable for achieving predictable ovulation timing. We’ve observed excellent oocyte maturation rates and reduced variability in luteal phase support requirements.” — Reproductive Endocrinologist, IVF Center

“The high purification standard significantly reduces injection site reactions compared to earlier formulations. Patients appreciate the decreased discomfort, and we’ve noted fewer mild allergic responses in sensitive individuals.” — Clinical Nurse Specialist, Fertility Clinic

“In our andrology practice, Hucog HP provides dependable stimulation for spermatogenesis in hypogonadotropic males. The multiple strength options allow for precise dose titration based on individual testosterone response.” — Andrologist, Male Fertility Center

“The manufacturing consistency and rigorous quality control measures give us confidence in treatment outcomes. We’ve maintained high success rates with minimal batch-to-batch variation over five years of use.” — Laboratory Director, ART Facility